TY - JOUR AU - Webb S. AU - Weatherall M. AU - Beasley R. AU - Bellomo R. AU - McArthur C. AU - Young P. AU - McGuinness S. AU - Henderson S. AU - Saxena M. AU - Myburgh J AU - Hammond N. AU - Freebairn R. AU - van Haren F. AU - Holliday M. AU - Mackle D. AB -

Background Acetaminophen is a common therapy for fever in patients in the intensive care unit (ICU) who have probable infection, but its effects are unknown. Methods We randomly assigned 700 ICU patients with fever (body temperature, >/=38 degrees C) and known or suspected infection to receive either 1 g of intravenous acetaminophen or placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death. The primary outcome was ICU-free days (days alive and free from the need for intensive care) from randomization to day 28. Results The number of ICU-free days to day 28 did not differ significantly between the acetaminophen group and the placebo group: 23 days (interquartile range, 13 to 25) among patients assigned to acetaminophen and 22 days (interquartile range, 12 to 25) among patients assigned to placebo (Hodges-Lehmann estimate of absolute difference, 0 days; 96.2% confidence interval [CI], 0 to 1; P=0.07). A total of 55 of 345 patients in the acetaminophen group (15.9%) and 57 of 344 patients in the placebo group (16.6%) had died by day 90 (relative risk, 0.96; 95% CI, 0.66 to 1.39; P=0.84). Conclusions Early administration of acetaminophen to treat fever due to probable infection did not affect the number of ICU-free days. (Funded by the Health Research Council of New Zealand and others; HEAT Australian New Zealand Clinical Trials Registry number, ACTRN12612000513819 .).

AD - From the Intensive Care Unit, Wellington Regional Hospital (P.Y., D.M.), Medical Research Institute of New Zealand (P.Y., R.F., M.H., S.H., D.M., C.M., S.M., R. Beasley), and Wellington School of Medicine, University of Otago (M.W.), Wellington, Intensive Care Unit, Hawke's Bay Hospital, Hastings (R.F.), Intensive Care Unit, Christchurch Hospital, Christchurch (S.H.), and the Department of Critical Care Medicine (C.M.) and Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; and the Critical Care and Trauma Division, George Institute for Global Health, Sydney (M.S., N.H., J.M.), Intensive Care Unit, St. George Hospital, Kogarah (M.S., J.M.), Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards (N.H.), and Faculty of Medicine, St. George Clinical School, University of New South Wales, Kensington (J.M.), NSW, Intensive Care Unit, Austin Hospital (R. Bellomo), the Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R. Bellomo), and Faculty of Medicine, University of Melbourne (R. Bellomo), Melbourne, VIC, the Intensive Care Unit, Canberra Hospital, Canberra, ACT (F.H.), and the Intensive Care Unit, Royal Perth Hospital, Perth (S.W.), and the School of Medicine and Pharmacology, University of Western Australia, Crawley (S.W.), WA - all in Australia. AN - 26436473 BT - New England Journal of Medicine. DP - NLM ET - 2015/10/06 LA - Eng LB - AUS
CCT
FY16 M1 - 23 N1 - Young, Paul
Saxena, Manoj
Bellomo, Rinaldo
Freebairn, Ross
Hammond, Naomi
van Haren, Frank
Holliday, Mark
Henderson, Seton
Mackle, Diane
McArthur, Colin
McGuinness, Shay
Myburgh, John
Weatherall, Mark
Webb, Steve
Beasley, Richard
HEAT Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
N Engl J Med. 2015 Oct 5. N2 -

Background Acetaminophen is a common therapy for fever in patients in the intensive care unit (ICU) who have probable infection, but its effects are unknown. Methods We randomly assigned 700 ICU patients with fever (body temperature, >/=38 degrees C) and known or suspected infection to receive either 1 g of intravenous acetaminophen or placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death. The primary outcome was ICU-free days (days alive and free from the need for intensive care) from randomization to day 28. Results The number of ICU-free days to day 28 did not differ significantly between the acetaminophen group and the placebo group: 23 days (interquartile range, 13 to 25) among patients assigned to acetaminophen and 22 days (interquartile range, 12 to 25) among patients assigned to placebo (Hodges-Lehmann estimate of absolute difference, 0 days; 96.2% confidence interval [CI], 0 to 1; P=0.07). A total of 55 of 345 patients in the acetaminophen group (15.9%) and 57 of 344 patients in the placebo group (16.6%) had died by day 90 (relative risk, 0.96; 95% CI, 0.66 to 1.39; P=0.84). Conclusions Early administration of acetaminophen to treat fever due to probable infection did not affect the number of ICU-free days. (Funded by the Health Research Council of New Zealand and others; HEAT Australian New Zealand Clinical Trials Registry number, ACTRN12612000513819 .).

PY - 2015 SN - 1533-4406 (Electronic)
0028-4793 (Linking) SP - 2215 EP - 24 T2 - New England Journal of Medicine. TI - Acetaminophen for Fever in Critically Ill Patients with Suspected Infection VL - 373 Y2 - FY16 ER -